Correction: Enhanced GAB2 Expression Is Associated with Improved Survival in High-grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

In this article (Mol Cancer Ther 2015;14:1495–1503), which appeared in the June 2015 issue of Molecular Cancer Therapeutics (1), an error in extracting the survival data led to a number of errors in the published data and the authors request the opportunity to correct the record.

The nature of the error is related to survival data from the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR3) randomized controlled trial in Germany. The authors were informed, postpublication, that there had been an error in extracting the survival data by the clinical trial data manager. The authors have since received the correctly extracted data with sample key, and have repeated the survival analysis.

The corrected data, which comprises 40% of the dataset for the first survival analysis and 17% of the combined second survival analysis, changes P values for all genes as would be expected, and some genes have altered statistical significance (Table 2; Supplementary Table S3). These differences affect only the first Results section, with the other four sections and the Discussion unchanged. The association of GAB2 expression with survival is reduced in the first subset analysis, but importantly, the association of GAB2 with overall survival by both Akaike Information Criterion analysis and in the large combined expression cohort is still statistically significant. Thus, the overall conclusions of the article remain unchanged.

The corrected results are addressed in the Abstract, the first Results section (including Fig. 1A), Table 2, Supplementary Figs. S1, S3, and S4, Supplementary Data S1, and Supplementary Table S3. In these changes, some genes were newly statistically significant.

The online version of the article has been updated to reflect the correction. The authors regret the error.